{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:01:23Z","timestamp":1781226083402,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04380-w","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:32:32Z","timestamp":1777365152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transarterial radioembolization versus transarterial chemoembolization for tumor control and survival outcomes in early to intermediate stage hepatocellular carcinoma: systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Wajahat","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid Amin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Bakar Hafeez","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"4380_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699\u2013710. https:\/\/doi.org\/10.1148\/radiol.211806. Epub 2022 Mar 8. PMID: 35258371.","journal-title":"Radiology"},{"issue":"6","key":"4380_CR2","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/liv.12750","volume":"35","author":"FT Kolligs","year":"2015","unstructured":"Kolligs FT, Bilbao JI, Jakobs T, I\u00f1arrairaegui M, Nagel JM, Rodriguez M, Haug A, D\u2019Avola D, op den Winkel M, Martinez-Cuesta A, Trumm C, Benito A, Tatsch K, Zech CJ, Hoffmann RT, Sangro B. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715\u201321. https:\/\/doi.org\/10.1111\/liv.12750 . Epub 2015 Jan 17. PMID: 25443863.","journal-title":"Liver Int"},{"issue":"2","key":"4380_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","volume":"38","author":"MB Pitton","year":"2015","unstructured":"Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, W\u00f6rns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352\u201360. https:\/\/doi.org\/10.1007\/s00270-014-1012-0 . Epub 2014 Nov 7. PMID: 25373796; PMCID: PMC4355443.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"4380_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155\u2013e11632. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.029. Epub 2016 Aug 27. PMID: 27575820; PMCID: PMC5124387.","journal-title":"Gastroenterology"},{"key":"4380_CR5","doi-asserted-by":"publisher","unstructured":"Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2016;39(11):1580\u20131588. https:\/\/doi.org\/10.1007\/s00270-016-1426-y. Epub 2016 Sep 1. Erratum in: Cardiovasc Intervent Radiol. 2017;40(9):1487. doi: 10.1007\/s00270-017-1693-2. PMID: 27586657.","DOI":"10.1007\/s00270-016-1426-y"},{"issue":"12","key":"4380_CR6","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","volume":"22","author":"C Lance","year":"2011","unstructured":"Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(12):1697\u2013705. Epub 2011 Oct 8. PMID: 21983055.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"4380_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jvir.2009.10.013","volume":"21","author":"DA Kooby","year":"2010","unstructured":"Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(2):224\u201330. Epub 2009 Dec 21. PMID: 20022765.","journal-title":"J Vasc Interv Radiol"},{"issue":"18","key":"4380_CR8","doi-asserted-by":"publisher","first-page":"770","DOI":"10.4254\/wjh.v8.i18.770","volume":"8","author":"A Facciorusso","year":"2016","unstructured":"Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol. 2016;8(18):770\u20138. https:\/\/doi.org\/10.4254\/wjh.v8.i18.770. PMID: 27366304; PMCID: PMC4921799.","journal-title":"World J Hepatol"},{"key":"4380_CR9","doi-asserted-by":"crossref","unstructured":"Saxena A, Meteling B, Kapoor J, Golani S, Danta M, Morris DL, Bester L. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. Int J Surg. 2014;12(12):1403-8. doi: 10.1016\/j.ijsu.2014.07.269. Epub 2014 Aug 1. PMID: 25091398.","DOI":"10.1016\/j.ijsu.2014.07.269"},{"issue":"11","key":"4380_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3748\/wjg.14.1664","volume":"14","author":"SM Ibrahim","year":"2008","unstructured":"Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008;14(11):1664\u20139. https:\/\/doi.org\/10.3748\/wjg.14.1664 . PMID: 18350597; PMCID: PMC2695906.","journal-title":"World J Gastroenterol"},{"key":"4380_CR11","doi-asserted-by":"publisher","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132. Epub 2010 Feb 19. PMID: 20175033; PMCID: PMC12268942.","DOI":"10.1055\/s-0030-1247132"},{"key":"4380_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13 . PMID: 15840177; PMCID: PMC1097734.","journal-title":"BMC Med Res Methodol"},{"key":"4380_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135 . PMID: 25524443; PMCID: PMC4383202.","journal-title":"BMC Med Res Methodol"},{"key":"4380_CR14","doi-asserted-by":"publisher","unstructured":"Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res. 2013;2(4):435\u2009\u2013\u200944. https:\/\/doi.org\/10.2217\/cer.13.37. PMID: 24236684.","DOI":"10.2217\/cer.13.37"},{"issue":"4","key":"4380_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jhep.2013.05.025","volume":"59","author":"R Golfieri","year":"2013","unstructured":"Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S. European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59(4):753\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2013.05.025 . Epub 2013 May 23. PMID: 23707371.","journal-title":"J Hepatol"},{"key":"4380_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","volume":"100","author":"Z Jia","year":"2018","unstructured":"Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018;100:23\u20139. https:\/\/doi.org\/10.1016\/j.ejrad.2018.01.012. Epub 2018 Jan 9. PMID: 2949607.","journal-title":"Eur J Radiol"},{"issue":"3","key":"4380_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.20892\/j.issn.2095-3941.2017.0177","volume":"15","author":"Y Yang","year":"2018","unstructured":"Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med. 2018;15(3):299\u2013310. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0177 . PMID: 30197797; PMCID: PMC6121048.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"4380_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers12040897","volume":"12","author":"A Facciorusso","year":"2020","unstructured":"Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: a propensity score analysis. Cancers (Basel). 2020;12(4):897. https:\/\/doi.org\/10.3390\/cancers12040897. PMID: 32272656; PMCID: PMC7226318.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4380_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3978\/j.issn.2078-6891.2015.056","volume":"6","author":"MS Bhangoo","year":"2015","unstructured":"Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette C. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2015;6(5):469\u201378. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.056 . PMID: 26487939; PMCID: PMC4570909.","journal-title":"J Gastrointest Oncol"},{"key":"4380_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/JHC.S248314","volume":"7","author":"A Teyateeti","year":"2020","unstructured":"Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival outcomes for Yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2020;7:117\u201331. PMID: 32984089; PMCID: PMC7500841.","journal-title":"J Hepatocell Carcinoma"},{"issue":"6","key":"4380_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jvir.2017.02.018","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, Vaidya S, Monsky WL, Park JO, Bhattacharya R, Hippe DS, Harris WP. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol. 2017;28(6):777\u2013e7851. https:\/\/doi.org\/10.1016\/j.jvir.2017.02.018. Epub 2017 Mar 30. PMID: 28365172.","journal-title":"J Vasc Interv Radiol"},{"key":"4380_CR22","doi-asserted-by":"publisher","unstructured":"Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2016;2:CD011313. doi: 10.1002\/14651858.CD011313.pub2. Update in: Cochrane Database Syst Rev. 2020;1:CD011313. https:\/\/doi.org\/10.1002\/14651858.CD011313.pub3. PMID: 26905230.","DOI":"10.1002\/14651858.CD011313.pub3"},{"issue":"1","key":"4380_CR23","first-page":"239","volume":"36","author":"O Akinwande","year":"2016","unstructured":"Akinwande O, Philips P, Scoggins C, Martin RC. Radioembolization versus chemoembolization (DEBDOX) for the treatment of unresectable hepatocellular carcinoma: a propensity matched study. Anticancer Res. 2016;36(1):239\u201346. PMID: 26722049.","journal-title":"Anticancer Res"},{"issue":"1","key":"4380_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1055\/s-2006-939842","volume":"23","author":"RJ Lewandowski","year":"2006","unstructured":"Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23(1):64\u201372. https:\/\/doi.org\/10.1055\/s-2006-939842 . PMID: 21326721; PMCID: PMC3036309.","journal-title":"Semin Intervent Radiol"},{"issue":"2","key":"4380_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2472062029","volume":"247","author":"KT Sato","year":"2008","unstructured":"Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres\u2013safety, efficacy, and survival. Radiology. 2008;247(2):507\u201315. https:\/\/doi.org\/10.1148\/radiol.2472062029 . Epub 2008 Mar 18. PMID: 18349311.","journal-title":"Radiology"},{"issue":"6","key":"4380_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","volume":"33","author":"DA Schartz","year":"2022","unstructured":"Schartz DA, Porter M, Schartz E, Kallas J, Gupta A, Butani D, Cantos A. Transarterial Yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol. 2022;33(6):679\u201386. Epub 2022 Feb 25. PMID: 35219834.","journal-title":"J Vasc Interv Radiol"},{"key":"4380_CR27","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.2147\/OTT.S137519","volume":"10","author":"C Meyer","year":"2017","unstructured":"Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther. 2017;10:4773\u201385. PMID: 29033589; PMCID: PMC5628695.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"4380_CR28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.surg.2020.12.012","volume":"169","author":"Y Bekki","year":"2021","unstructured":"Bekki Y, Marti J, Toshima T, Lewis S, Kamath A, Argiriadi P, Simpson W, Facciuto L, Patel RS, Gunasekaran G, Kim E, Schiano TD, Facciuto ME. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery. 2021;169(5):1044\u201351. Epub 2021 Feb 27. PMID: 33648768.","journal-title":"Surgery"},{"issue":"8","key":"4380_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jvir.2016.03.046","volume":"27","author":"GE Johnson","year":"2016","unstructured":"Johnson GE, Monsky WL, Valji K, Hippe DS, Padia SA. Yttrium-90 radioembolization as a salvage treatment following chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2016;27(8):1123\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2016.03.046. Epub 2016 Jun 16. PMID: 27321889.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"4380_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.4254\/wjh.v7.i5.738","volume":"7","author":"C Mosconi","year":"2015","unstructured":"Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7(5):738\u201352. https:\/\/doi.org\/10.4254\/wjh.v7.i5.738 . PMID: 25914774; PMCID: PMC4404379.","journal-title":"World J Hepatol"},{"key":"4380_CR31","doi-asserted-by":"publisher","unstructured":"Camm\u00e0 C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Crax\u00ec A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47\u201354. https:\/\/doi.org\/10.1148\/radiol.2241011262. PMID: 12091661.","DOI":"10.1148\/radiol.2241011262"},{"key":"4380_CR32","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015;9(5):289\u2009\u2013\u200998. https:\/\/doi.org\/10.5582\/bst.2015.01089. PMID: 26559021.","DOI":"10.5582\/bst.2015.01089"},{"issue":"1","key":"4380_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12876-022-02396-6","volume":"22","author":"JC Alonso","year":"2022","unstructured":"Alonso JC, Casans I, Gonz\u00e1lez FM, Fuster D, Rodr\u00edguez A, S\u00e1nchez N, Oyag\u00fcez I, Burgos R, Williams AO, Espinoza N. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review. BMC Gastroenterol. 2022;22(1):326. https:\/\/doi.org\/10.1186\/s12876-022-02396-6 . PMID: 35780112; PMCID: PMC9250253.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4380_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00432-021-03665-9","volume":"148","author":"ABH Bhatti","year":"2022","unstructured":"Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol. 2022;148(1):245\u201353. https:\/\/doi.org\/10.1007\/s00432-021-03665-9 . Epub 2021 Jun 12. PMID: 34117916; PMCID: PMC8752562.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"4380_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/tri.13586","volume":"33","author":"M Assalino","year":"2020","unstructured":"Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int. 2020;33(5):567\u201375. https:\/\/doi.org\/10.1111\/tri.13586 . Epub 2020 Feb 20. PMID: 31994238.","journal-title":"Transpl Int"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04380-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04380-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04380-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:23:58Z","timestamp":1781223838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04380-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4380"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04380-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required, as this review was based exclusively on pre-existing published data and no new patient involvement occurred.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to particpate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}